{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:39:37Z","timestamp":1780565977594,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Manitob"},{"name":"Health Sciences Centre"},{"name":"National Microbiology Laboratory"},{"name":"Tetraphase Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.diagmicrobio.2017.12.013","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T01:54:26Z","timestamp":1513907666000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014\u20132015"],"prefix":"10.1016","volume":"91","author":[{"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Sutcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0005","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1128\/AAC.04809-14","article-title":"Activity of eravacycline against Enterobactericeae and Acinetobacter baumannii including multidrug-resistant isolates from New York City","volume":"59","author":"Abdallah","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.12.013_bb0010","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically\u2014tenth edition: approved standard M07-A10","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2017.12.013_bb0015","series-title":"Performance standards for antimicrobial susceptibility testing. Twenty-sixth informational supplement. Document M100-S26","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0020","doi-asserted-by":"crossref","first-page":"i57","DOI":"10.1093\/jac\/dkt027","article-title":"Molecular epidemiology of extended-spectrum \u03b2-lactamase AmpC \u03b2-lactamase and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007\u20132011","volume":"68","author":"Denisuik","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0025","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14787210.2016.1204911","article-title":"The antibiotic pipeline for multi-drug resistant gram-negative bacteria: what can we expect?","volume":"14","author":"Falagas","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0030","doi-asserted-by":"crossref","first-page":"6989","DOI":"10.1128\/AAC.01646-16","article-title":"Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1","volume":"60","author":"Fyfe","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.12.013_bb0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2008\/754249","article-title":"A preliminary guideline for the assignment of methicillin-resistant Staphylococcus aureus to a Canadian pulsed-field gel electrophoresis epidemic type using spa typing","volume":"19","author":"Golding","year":"2008","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0040","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.06187-11","article-title":"Target and resistance based mechanistic studies with TP-434 a novel fluorocycline antibiotic","volume":"56","author":"Grossman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0045","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1128\/AAC.04354-14","article-title":"Eravacycline (TP-434) is efficacious in animal models of infection","volume":"59","author":"Grossman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0050","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1128\/AAC.04967-14","article-title":"Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli","volume":"59","author":"Grossman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0055","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1128\/AAC.02403-15","article-title":"Activity of eravacycline against Escherichia coli clinical isolates collected from US veterans in 2011 I relation to coresistance phenotype and sequence type 131 genotype","volume":"60","author":"Johnson","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0060","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0065","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/AAC.00366-16","article-title":"Antibacterial efficacy of eravacycline in vivo against gram-positive and gram-negative organisms","volume":"60","author":"Monogue","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0070","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/jac\/dkt026","article-title":"Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada","volume":"68","author":"Nichol","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0075","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1128\/AAC.00384-15","article-title":"Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007\u20132013)","volume":"59","author":"Simner","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0080","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2 randomized double blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adults community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.12.013_bb0085","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","author":"Solomkin","year":"2016","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0090","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434) a novel fluorocycline against hospital and community pathogens","volume":"59","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.12.013_bb0095","first-page":"1","article-title":"Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae","author":"Thaden","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.diagmicrobio.2017.12.013_bb0100","unstructured":"Tsai L, Zervos M, Miller L, et al. Intravenous eravacycline compared to intravenous levofloxacin for the treatment of complicated urinary tract infection (cUTI): subgroup analysis of a randomized double-blind phase 3 trial (IGNITE2). Abstract. MO-265. ASM microbe; June 16\u201320, 2016, Boston, MA"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0105","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1021\/jm201465w","article-title":"Fluorocyclines 1,7 fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent broad spectrum antibacterial agent","volume":"55","author":"Xiao","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.diagmicrobio.2017.12.013_bb0110","series-title":"Tygacil (tigecycline)\u2014tigecycline injection, powder, lyophilized, for solution. Prescribing information","author":"Wyeth Pharmaceuticals Inc","year":"2016"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0115","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ja.2016.73","article-title":"In vitro susceptibility of \u03b2-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline","volume":"69","author":"Zhang","year":"2016","journal-title":"J Antibiot (Tokyo)"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14787210.4.1.9","article-title":"Tigecycline: a novel glycylcycline antibiotic","volume":"4","author":"Zhanel","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/dkt022","article-title":"Antimicrobial susceptibility of 22,746 pathogens from Canadian hospitals; results of the CANWARD 2007-2011 study","volume":"68","author":"Zhanel","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2017.12.013_bb0130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317304091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317304091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T19:23:15Z","timestamp":1589829795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889317304091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0732889317304091"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.12.013","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014\u20132015","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}